cabozantinib

Exelixis initiates phase 3 trial of Cabozantinib/Atezolizumab combo in prostate cancer
Exelixis initiates phase 3 trial of Cabozantinib/Atezolizumab combo in prostate cancer
Pharmaceutical Business Review
Exelixis
cabozantinib
Cabometyx
Tecentriq
metastatic castration-resistant prostate cancer
clinical trials
Flag link:
Exelixis Reports Positive Results in Metastatic Castration-Resistant Prostate Cancer Study
Exelixis Reports Positive Results in Metastatic Castration-Resistant Prostate Cancer Study
Motley Fool
Exelixis
prostate cancer
metastatic castration-resistant prostate cancer
cabozantinib
Cabometyx
Flag link:
Exelixis Hits Blockbuster Status
Exelixis Hits Blockbuster Status
Motley Fool
Exelixis
cabozantinib
Cabometx
kidney cancer
liver cancer
Cometriq
thyroid cancer
Flag link:
Exelixis initiates phase 3 trial of cabozantinib in advanced renal cell carcinoma
Exelixis initiates phase 3 trial of cabozantinib in advanced renal cell carcinoma
Pharmaceutical Business Review
Exelixis
clinical trials
cabozantinib
Cabometyx
advanced renal cell carcinoma
Flag link:
FDA Fast Tracks Calithera Biosciences' CB-839 in Combination with Cabozantinib for Advanced Renal Cell Carcinoma
FDA Fast Tracks Calithera Biosciences' CB-839 in Combination with Cabozantinib for Advanced Renal Cell Carcinoma
CP Wire
Calithera Biosciences
CB-839
cabozantinib
metastatic renal cell carcinoma
Flag link:
2 Big Reasons Exelixis, Inc. Soared 22% in January
2 Big Reasons Exelixis, Inc. Soared 22% in January
Motley Fool
Exelixis
Cotellic
Roche
cabozantinib
Takeda
Flag link:
On a deal spree, Takeda grabs Japanese cabo rights in $145M pact with Exelixis
On a deal spree, Takeda grabs Japanese cabo rights in $145M pact with Exelixis
Endpoints
Takeda
Japan
cabozantinib
Exelixis
Flag link:
3 Things Exelixis Must Do to Survive and Thrive in 2017
3 Things Exelixis Must Do to Survive and Thrive in 2017
Motley Fool
Exelixis
cabozantinib
Cabometyx
Cometriq
Flag link:
Key FDA Decisions and Trial Results Expected in October
Key FDA Decisions and Trial Results Expected in October
24/7 Wall St
FDA
clinical trials
Exelixis
cabozantinib
Cobimetinib
Celldex Therapeutics
CDX-011
Cerulean Pharma
CRLX101
Medivation
Xtandi
Palatin
bermelanotide
Rexahn
RX-3117
Anthera Pharmaceuticals
Flag link:
Key FDA Decisions and Trial Results Coming in the Next 2 Months
Key FDA Decisions and Trial Results Coming in the Next 2 Months
24/7 Wall St
FDA
clinical trials
Array Biopharma
binimetinib
Mast Therapeutics
Novavax
RSV F vaccine
Threshold Pharmaceuticals
tarloxotinib
Cerulean Pharma
Vertex Pharmaceuticals
Orkambi
Exelixis
cabozantinib
Cobimetinib
Medivation
Xtandi
Celldex
Flag link:
Key FDA Decisions and Trial Results Expected in October
Key FDA Decisions and Trial Results Expected in October
24/7 Wall St
FDA
clinical trials
cabozantinib
Cobimetinib
Exelixis
Medivation
Xtandi
Celldex Therapeutics
glemba
Palatin
bremelanotide
CRLX101
Cerulean Pharma
Anthera Pharmaceuticals
Flag link:
3 Big Pharma Stocks With Credible Threats to Their Blockbusters
3 Big Pharma Stocks With Credible Threats to Their Blockbusters
24/7 Wall St
Pfizer
renal cancer
Sutent
cabozantinib
Exelixis
AstraZeneca
Faslodex
breast cancer
Atossa Genetics
Merck
Zetia
Mylan Labs
Flag link:
Exelixis Rises on Positive Late-Stage Trial Results
Exelixis Rises on Positive Late-Stage Trial Results
24/7 Wall St
Exelixis
cabozantinib
renal cell carcinoma
clinical trials
Flag link:
FDA Grants Breakthrough Therapy Designation to Exelixis’ Cabozantinib for the Treatment of Renal Cell Carcinoma in Patients Who Received One Prior Therapy
FDA Grants Breakthrough Therapy Designation to Exelixis’ Cabozantinib for the Treatment of Renal Cell Carcinoma in Patients Who Received One Prior Therapy
Yahoo
FDA
Exelixis
breakthrough therapies
renal cell carcinoma
cabozantinib
Flag link:
6 Key Cancer Winners From ASCO Presentations
6 Key Cancer Winners From ASCO Presentations
24/7 Wall St
ASCO
Immunogen
mirevtuximab soravtansine
ONT-380
Oncothyreon
cabozantinib
Exelixis
VB-111
Vascular Biogenics
Immunomedics
sacituzumab govitecan
pacritinib
CTI BioPharma
Flag link:
Exelixis drops 15% after prostate cancer drug candidate fails Phase 3
Exelixis drops 15% after prostate cancer drug candidate fails Phase 3
Seeking Alpha
Exelixis
prostate cancer
cabozantinib
Flag link:
Exelixis Drug Fails Pivotal Prostate Cancer Study; Laying Off 70% of Employees
Exelixis Drug Fails Pivotal Prostate Cancer Study; Laying Off 70% of Employees
TheStreet.com
Exelixis
prostate cancer
cabozantinib
layoffs
Flag link:
Disappointment Over Prostate Cancer Drug Study Weigh Heavily on Exelixis
Disappointment Over Prostate Cancer Drug Study Weigh Heavily on Exelixis
TheStreet.com
prostate cancer
Exelixis
cabozantinib
Flag link:
Exelixis achieves enrollment target for phase 3 trial of cabozantinib
Exelixis achieves enrollment target for phase 3 trial of cabozantinib
Yahoo/Fly on the Wall
Exelixis
cabozantinib
metastatic castration-resistant prostate cancer
Flag link:
Exelixis Announces Presentation of Updated Phase 2 Data for Cabozantinib in Men with Heavily-Pretreated Metastatic Castration-Resistant Prostate Cancer
Exelixis Announces Presentation of Updated Phase 2 Data for Cabozantinib in Men with Heavily-Pretreated Metastatic Castration-Resistant Prostate Cancer
Yahoo/BusinessWire
Exelixis
cabozantinib
prostate cancer
Flag link:

Pages